MGI Pharma MOGN New patents, anti cancer Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : MGI Pharma MOGN New patents, anti cancer

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Icebrg who wrote (1515)	9/2/2004 1:56:52 PM
From: Icebrg	Read Replies (1) of 1826

MGI Pharma "outperform" Thursday, September 02, 2004 8:33:15 AM ET Robert W. Baird NEW YORK, September 2 (New Ratings) - Analysts at Robert W Baird maintain their "outperform" rating on MGI Pharma Inc (MOGN.NAS). The target price is set to $32. In a research note published yesterday, the analysts mention that the company recently announced the acquisition of two private holding companies, Zycos and Asgen. The company also announced its intention to invest approximately $40 million in the pharmaceutical company, SuperGen, in order to obtain access to SuperGen’s cancer treatment drug, Dacogen, the analysts state. The deal is expected to help MGI Pharma make a transition from a single-product company to a multi-product company, Robert W Baird adds

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next